Psychotic Disorders Clinical Trial
Official title:
Evaluation of a Brief Intervention to Improve Engagement and Recovery for At-risk Youth Enrolled in Early Intervention Services for Psychosis .
Negative experiences with healthcare prior to referral to early intervention services for psychosis (EIS) have been linked to poor engagement and clinical outcomes. Recent research indicates that young adults who come to EIS services thru emergency departments, urgent care, or inpatient services have significantly greater rates of future use of these services as well as more negative perceptions of EIS and diminished engagement in treatment compared to young adults referred to EIS by other pathways. These findings suggest a need for additional support to be provided to EIS patients, especially those with prior negative healthcare experiences, to maximize treatment engagement and outcomes. A recent USA-based trial of a brief intervention addressing barriers to disengagement (Just Do You), including prior negative healthcare experiences, showed promise in improving engagement and recovery. This project seeks to adapt and evaluate the Just Do You intervention to a young adult early psychosis population in Nova Scotia. The investigators aim to recruit young adults from the Nova Scotia Early Psychosis Program to engage in 2 psychotherapy/psychoeducation sessions co-led by a clinician and peer support worker. Following the intervention, the investigators will measure improvements in participants' engagement and recovery to determine the effectiveness of the program. Outcomes between participants with negative prior healthcare experiences and those without will be compared to assess differential impact of the intervention for high-risk sub-groups. This project has the potential to improve patients' engagement in EIS care and enhance recovery outcomes for young adults.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | August 1, 2026 |
Est. primary completion date | October 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 35 Years |
Eligibility | Inclusion Criteria: - Within first 3-12 months of treatment in early intervention services. - Diagnosis of a psychotic disorder using the DSM-5 criteria for schizophrenia spectrum and other psychotic disorders (e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, unspecified schizophrenia spectrum and other psychotic disorder, etc.) - Diagnosis within past 5 years. Exclusion Criteria: - Primary diagnosis that is not a psychotic disorder. - Outside of age limits. - Intellectual Disability (IQ < 70) |
Country | Name | City | State |
---|---|---|---|
Canada | Nova Scotia Early Psychosis Program (NSEPP) | Halifax | Nova Scotia |
Lead Sponsor | Collaborator |
---|---|
Nova Scotia Health Authority | Queen Elizabeth II Health Sciences Centre |
Canada,
Abelson J, Li K, Wilson G, Shields K, Schneider C, Boesveld S. Supporting quality public and patient engagement in health system organizations: development and usability testing of the Public and Patient Engagement Evaluation Tool. Health Expect. 2016 Aug;19(4):817-27. doi: 10.1111/hex.12378. Epub 2015 Jun 25. — View Citation
Addington J, Van Mastrigt S, Hutchinson J, Addington D. Pathways to care: help seeking behaviour in first episode psychosis. Acta Psychiatr Scand. 2002 Nov;106(5):358-64. doi: 10.1034/j.1600-0447.2002.02004.x. — View Citation
Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993 Jun;150(6):873-9. doi: 10.1176/ajp.150.6.873. — View Citation
Anderson KK, Fuhrer R, Schmitz N, Malla AK. Determinants of negative pathways to care and their impact on service disengagement in first-episode psychosis. Soc Psychiatry Psychiatr Epidemiol. 2013 Jan;48(1):125-36. doi: 10.1007/s00127-012-0571-0. Epub 2012 Sep 14. — View Citation
Becker-Blease KA, Freyd JJ. Research participants telling the truth about their lives: the ethics of asking and not asking about abuse. Am Psychol. 2006 Apr;61(3):218-26. doi: 10.1037/0003-066X.61.3.218. — View Citation
Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. Br J Psychiatry Suppl. 2005 Aug;48:s116-9. doi: 10.1192/bjp.187.48.s116. — View Citation
Boyd JE, Adler EP, Otilingam PG, Peters T. Internalized Stigma of Mental Illness (ISMI) scale: a multinational review. Compr Psychiatry. 2014 Jan;55(1):221-31. doi: 10.1016/j.comppsych.2013.06.005. Epub 2013 Sep 21. — View Citation
Carr S, Hardy A, Fornells-Ambrojo M. The Trauma and Life Events (TALE) checklist: development of a tool for improving routine screening in people with psychosis. Eur J Psychotraumatol. 2018 Sep 11;9(1):1512265. doi: 10.1080/20008198.2018.1512265. eCollection 2018. — View Citation
Corrigan PW, Salzer M, Ralph RO, Sangster Y, Keck L. Examining the factor structure of the recovery assessment scale. Schizophr Bull. 2004;30(4):1035-41. doi: 10.1093/oxfordjournals.schbul.a007118. — View Citation
D. K. Yatchmenoff, "Measuring client engagement from the client's perspective in nonvoluntary child protective services," Res. Soc. Work Pract., vol. 15, no. 2, pp. 84-96, 2005.
Dixon LB, Holoshitz Y, Nossel I. Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry. 2016 Feb;15(1):13-20. doi: 10.1002/wps.20306. Erratum In: World Psychiatry. 2016 Jun;15(2):189. — View Citation
Hammer, J. H., & Toland, M. D. (2017). Internal structure and reliability of the Internalized Stigma of Mental Illness Scale (ISMI-29) and Brief Versions (ISMI-10, ISMI-9) among Americans with depression. Stigma and Health, 2(3), 159.
Jones N, Gius BK, Shields M, Collings S, Rosen C, Munson M. Investigating the impact of involuntary psychiatric hospitalization on youth and young adult trust and help-seeking in pathways to care. Soc Psychiatry Psychiatr Epidemiol. 2021 Nov;56(11):2017-2027. doi: 10.1007/s00127-021-02048-2. Epub 2021 Mar 9. — View Citation
Kaplan K, Salzer MS, Brusilovskiy E. Community participation as a predictor of recovery-oriented outcomes among emerging and mature adults with mental illnesses. Psychiatr Rehabil J. 2012 Winter;35(3):219-29. doi: 10.2975/35.3.2012.219.229. — View Citation
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261. — View Citation
Kontopantelis E, Doran T, Springate DA, Buchan I, Reeves D. Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis. BMJ. 2015 Jun 9;350:h2750. doi: 10.1136/bmj.h2750. — View Citation
Liu S, Rovine MJ, Molenaar PC. Selecting a linear mixed model for longitudinal data: repeated measures analysis of variance, covariance pattern model, and growth curve approaches. Psychol Methods. 2012 Mar;17(1):15-30. doi: 10.1037/a0026971. Epub 2012 Jan 16. — View Citation
Macbeth A, Gumley A, Schwannauer M, Fisher R. Service engagement in first episode psychosis: clinical and premorbid correlates. J Nerv Ment Dis. 2013 May;201(5):359-64. doi: 10.1097/NMD.0b013e31828e0e19. — View Citation
MacDonald K, Fainman-Adelman N, Anderson KK, Iyer SN. Pathways to mental health services for young people: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2018 Oct;53(10):1005-1038. doi: 10.1007/s00127-018-1578-y. Epub 2018 Aug 22. — View Citation
Matheson FI, Dunn JR, Smith KL, Moineddin R, Glazier RH. Development of the Canadian Marginalization Index: a new tool for the study of inequality. Can J Public Health. 2012 Apr 30;103(8 Suppl 2):S12-6. doi: 10.1007/BF03403823. — View Citation
McRee B, Babor TF, Lynch ML, Vendetti JA. Reliability and Validity of a Two-Question Version of the World Health Organization's Alcohol, Smoking and Substance Involvement Screening Test: The ASSIST-FC. J Stud Alcohol Drugs. 2018 Jul;79(4):649-657. — View Citation
Michel P, Baumstarck K, Auquier P, Amador X, Dumas R, Fernandez J, Lancon C, Boyer L. Psychometric properties of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia. BMC Psychiatry. 2013 Sep 22;13:229. doi: 10.1186/1471-244X-13-229. — View Citation
Minsky SK, Lu W, Silverstein SM, Gara M, Gottlieb JD, Mueser KT. Service Use and Self-Reported Symptoms Among Persons With Positive PTSD Screens and Serious Mental Illness. Psychiatr Serv. 2015 Aug 1;66(8):845-50. doi: 10.1176/appi.ps.201400192. Epub 2015 Apr 15. — View Citation
Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000 Apr;101(4):323-9. — View Citation
Mueser KT, Lu W, Rosenberg SD, Wolfe R. The trauma of psychosis: posttraumatic stress disorder and recent onset psychosis. Schizophr Res. 2010 Feb;116(2-3):217-27. doi: 10.1016/j.schres.2009.10.025. Epub 2009 Nov 24. — View Citation
Munson MR, Jaccard J, Moore KL, Rodwin AH, Shimizu R, Cole AR, Scott LD Jr, Narendorf SC, Davis M, Gilmer T, Stanhope V. Impact of a brief intervention to improve engagement in a recovery program for young adults with serious mental illness. Schizophr Res. 2022 Dec;250:104-111. doi: 10.1016/j.schres.2022.11.008. Epub 2022 Nov 15. — View Citation
Munson MR, Jaccard JJ, Scott LD Jr, Narendorf SC, Moore KL, Jenefsky N, Cole A, Davis M, Gilmer T, Shimizu R, Pleines K, Cooper K, Rodwin AH, Hylek L, Amaro A. Engagement intervention versus treatment as usual for young adults with serious mental illness: a randomized pilot trial. Pilot Feasibility Stud. 2020 Jul 23;6:107. doi: 10.1186/s40814-020-00650-w. eCollection 2020. — View Citation
Priebe S, Katsakou C, Amos T, Leese M, Morriss R, Rose D, Wykes T, Yeeles K. Patients' views and readmissions 1 year after involuntary hospitalisation. Br J Psychiatry. 2009 Jan;194(1):49-54. doi: 10.1192/bjp.bp.108.052266. — View Citation
Priebe S, Katsakou C, Glockner M, Dembinskas A, Fiorillo A, Karastergiou A, Kiejna A, Kjellin L, Nawka P, Onchev G, Raboch J, Schuetzwohl M, Solomon Z, Torres-Gonzalez F, Wang D, Kallert T. Patients' views of involuntary hospital admission after 1 and 3 months: prospective study in 11 European countries. Br J Psychiatry. 2010 Mar;196(3):179-85. doi: 10.1192/bjp.bp.109.068916. — View Citation
Rodrigues R, Anderson KK. The traumatic experience of first-episode psychosis: A systematic review and meta-analysis. Schizophr Res. 2017 Nov;189:27-36. doi: 10.1016/j.schres.2017.01.045. Epub 2017 Feb 14. — View Citation
Salzer MS, Brusilovskiy E. Advancing recovery science: reliability and validity properties of the Recovery Assessment Scale. Psychiatr Serv. 2014 Apr 1;65(4):442-53. doi: 10.1176/appi.ps.201300089. — View Citation
Seed T, Fox JR, Berry K. The experience of involuntary detention in acute psychiatric care. A review and synthesis of qualitative studies. Int J Nurs Stud. 2016 Sep;61:82-94. doi: 10.1016/j.ijnurstu.2016.05.014. Epub 2016 Jun 4. — View Citation
Senger B, Pencer A, Crocker CE, Simon P, Taylor B, Tibbo PG. The role of referral pathway to early intervention services for psychosis on 2-year inpatient and emergency service use. J Psychiatr Res. 2024 Apr;172:340-344. doi: 10.1016/j.jpsychires.2024.02.035. Epub 2024 Feb 28. — View Citation
Silva B, Bachelard M, Amoussou JR, Martinez D, Bonalumi C, Bonsack C, Golay P, Morandi S. Feeling coerced during voluntary and involuntary psychiatric hospitalisation: A review and meta-aggregation of qualitative studies. Heliyon. 2023 Feb 2;9(2):e13420. doi: 10.1016/j.heliyon.2023.e13420. eCollection 2023 Feb. — View Citation
Statistics Canada. 2019. "The Canadian Index of Multiple Deprivation". Statistics Canada Catalogue no. 45-20-0001.
Street LL, Luoma JB. Control groups in psychosocial intervention research: ethical and methodological issues. Ethics Behav. 2002;12(1):1-30. doi: 10.1207/S15327019EB1201_1. — View Citation
W. Guy, "Clinical Global Impression," in Assessment manual for psychopharmacology, Rockville, MD: US Department of Health, Education, and Welfare, 1976.
Weaver CG, Ravani P, Oliver MJ, Austin PC, Quinn RR. Analyzing hospitalization data: potential limitations of Poisson regression. Nephrol Dial Transplant. 2015 Aug;30(8):1244-9. doi: 10.1093/ndt/gfv071. Epub 2015 Mar 25. — View Citation
Weiss A, Steadman S, Mercier HD, Hansel TC, Chaudhry S, Clark I. Pathways to Care: How Help-Seeking Behaviors Relate to Duration of Untreated Psychosis and Treatment Engagement. Psychiatr Q. 2022 Jun;93(2):473-482. doi: 10.1007/s11126-021-09960-5. Epub 2021 Oct 20. — View Citation
West BT. Analyzing longitudinal data with the linear mixed models procedure in SPSS. Eval Health Prof. 2009 Sep;32(3):207-28. doi: 10.1177/0163278709338554. Epub 2009 Aug 13. — View Citation
WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002 Sep;97(9):1183-94. doi: 10.1046/j.1360-0443.2002.00185.x. — View Citation
* Note: There are 41 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Quantitative Engagement: Rate of Missed Appointments | In order to obtain an additional objective indicator of participants' treatment engagement, we will measure participants' rate of missed appointments 3-months prior and 6-months following intervention. Number of missed appointments will be compared for treatment vs control participants to assess whether the treatment intervention is associated with a reduction in missed appointments. | Number/rate of missed appointments will begin being measured 3-month's prior to involvement in the study and end 6-months following initial engagement in the study. | |
Other | Rate of Emergency Department Visits & Hospital Admissions | In addition, we will measure rate of hospitalization and ER visits (cumulative # of visits/person-month) over the same time frame (3-months prior and 6-months following intervention). Rate of ER and hospital admissions will be compared for treatment vs control participants to assess whether the treatment intervention is associated with a difference in urgent service use between the treatment and control group. | Number/rate of missed appointments will begin being measured 3-month's prior to involvement in the study and end 6-months following initial engagement in the study. | |
Primary | Yatchmenoff Client Engagement Scale - Modified | Participants' self-reported engagement in treatment is measured using a modified version of the Yatchmenoff Client Engagement Scale. Initially designed to assess engagement in child protective services, but previously modified and used in the initial Just Do You trial, modification of this scale will involve for this study slight changes to wording of questions to different care setting. This 19-item measure assesses respondents' perceptions of treatment and engagement in it across 4 dimensions using a 5-point likert scale with responses ranging from 1 - Strongly Disagree to 5 - Strongly Agree: Receptivity (Range: 4 - 20, with higher scores indicating increased receptivity to treatment) Buy-in (Range: 8 - 40, with higher scores indicating increased buy-in to treatment), Working relationship (Range: 4 - 20, with higher scores indicating perceptions of a stronger working relationship), and Trust (Range: 3 - 15, with higher scores indicating increased trust in care providers). | Administered at baseline (T0), 2 weeks follow up, 4 weeks follow-up and at end of study follow up at 4 months. | |
Primary | Recovery Assessment Scale - Revised (RAS-R) | Participants' recovery is measured using the 24-item revised version of the Recovery Assessment Scale (RAS-R). The RAS is a self-report assessment of individuals' recovery, previously determined to be valid for use with those experiencing serious mental illness. The RAS-R assesses respondents' perceptions of personal recovery in 5 domains: Personal confidence and hope, Willingness to ask for help, Goal and success orientation, Reliance on others, and No domination by symptoms. Responses are scored using a 5-point likert scale with responses ranging from 1 - Strongly Disagree to 5 - Strongly Agree. Total scores range from 24 - 120 with higher values indicating respondents' perceptions of more improved recovery. | Administered at baseline (T0), 2-weeks follow up, 4 weeks follow-up and at end of study follow up at 4 months. | |
Primary | 9-item Internalized Stigma of Mental Illness Inventory (ISMI-9) | Participants' internalized stigma will be measured using the abbreviated 9-item Internalized Stigma of Mental Illness Inventory (ISMI-9). The ISMI-9 is an abbreviated version of the original 29 item ISMI, that aims to assess degree of internalized/self stigma in those experiencing mental illness. Each item of the scale is measured on a 4-point Likert scale (1 - strongly disagree to 4 - strongly agree). Total are then divided by 9 to obtain an average score for internalized stigma with higher scores indicating greater degrees of internalized stigma for respondents (Range: 1 - 4). The 29-item version of this scale has been widely used in studies of stigma in early psychosis samples, but the abbreviated version will be used for this study to reduce burden of involvement on study participants. The 9-item version has been previously demonstrated to have adequate psychometric properties. | Administered at baseline (T0) and at end of study follow up at 4 months. | |
Secondary | Positive and Negative Syndrome Scale 6-item abbreviated version (PANSS-6) | Psychotic symptoms are measured using the Positive and Negative Syndrome Scale 6-item abbreviated version, a validated abbreviated version of the PANSS-30 gold standard measure of symptom severity in psychosis. This clinician-rated measure assesses respondents' symptom severity using 6-items from the original 30 item PANSS (P1-Delusions, P2-Conceptual disorganization, P3- Hallucinations, N1- Blunted affect, N4- Social withdrawal, N6 - Lack of spontaneity and flow of conversation). Item scores range from 1 - minimal symptoms to 7 - extreme symptoms with increased PANSS-6 total scores indicating more severe symptoms (Range: 6 - 42). | Administered at baseline (T0) and at end of study follow up at 4 months. | |
Secondary | Clinical Global Impression (CGI-I & CGI-S) | Assessment of participants global illness severity will be assessed using the CGI-S. The CGI-S is a 7-point clinician rated Likert scale that assesses individuals' overall illness severity relative those who the clinician has experienced with the same diagnosis (ranging from 1 = Normal, not at all ill to 7 = Extremely ill). The CGI-I is a 7-point clinician rated Likert scale that assesses an individual's global change in illness severity compared to a baseline rating prior to intervention (ranging from 1 = Very much improved to 7 = Very much worse). | Administered at baseline (T0) and at end of study follow up at 4 months. | |
Secondary | Social and Occupational Functioning Assessment Scale (SOFAS) | Functioning is measured using the Social and Occupational Functioning Assessment Scale (SOFAS). The SOFAS is a widely used, reliable, clinician determined, single item measure of individuals' social and occupational functioning independent of symptoms. The SOFAS is a 100-point single-item rating measure, subdivided into 10 equal intervals (Range: 0 - 100) with higher scores indicating improved functioning. | Administered at baseline (T0) and at end of study follow up at 4 months. | |
Secondary | Abbreviated Scale to Assess Unawareness in Mental Disorder (SUMD) | Participant insight will be measured using the Abbreviated Scale to Assess Unawareness in Mental Disorder (SUMD). This is a 9-item clinician administered measure of participants' insight which is commonly impaired in psychosis. The SUMD assesses insight along 3 core dimensions determined to: Awareness of the disease, Consequences and need for treatment; Awareness of symptoms. The scores are typically measured on a scale from 0 to 100, with higher scores indicating better insight. | Administered at baseline (T0) and at end of study follow up at 4 months. | |
Secondary | WHO Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) - FC | Participant substance use will be measured using A modified version of the WHO Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), called the ASSIST-FC. This measure asks participants about frequency of use and potential for misuse using two questions: "In the past 3 months, which of the following substances have you used?", "Has a friend or relative or anyone else ever expressed concern about your use of any substances?"). Possible answers range from "Never" to "Daily or almost daily" for the first question and for the second question, range from "No, never", "Yes, in the past 3 months," to "Yes, but not in the past 3 months." The full ASSIST is regularly used at the Nova Scotia Early Psychosis Program (NSEPP), but the shortened version will be used to decrease burden of study involvement for participants. | Administered at baseline (T0) and at end of study follow up at 4 months. | |
Secondary | The Trauma and Life Events (TALE) checklist | Experiences of Traumatic/Adverse Events Participants' experiences of lifetime traumatic events will be measured using The Trauma and Life Events (TALE) checklist. The TALE is a 21-item questionnaire, which assesses what adverse experiences participants have experienced, when they happened and the number of experiences of these events. Additionally, this questionnaire assesses the degree to which endorsed adverse events are affecting participants now in any way. | Administered at baseline (T0) | |
Secondary | Demographic Questionnaire | Participants' demographic characteristics will be assessed using a demographic form which will include questions about participants' age, ethnicity, migrant status, gender identity, and sexual orientation, as well as questions about past experiences with mental healthcare and referral source. In addition, participants postal code will be collected and used to extrapolate an estimate of socioeconomic status (SES) using The Canadian Index of Multiple Deprivation (CIMD). This index developed by Statistics Canada, uses postal code data to estimate individuals' SES using participants' geographical location on four dimensions: Residential instability, Economic dependency, Ethno-cultural composition, and Situational vulnerability. These dimensions based on available evidence and up-to date census data, and are widely used in Canadian health research as proxy multi-dimensional estimates of SES. | Administered at baseline (T0) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00226278 -
Safety Study of ORG 34517 for Major Depression With Psychotic Features
|
Phase 2 |